New Migraine Drug Ubrogepant Shows Promise in Early Symptom Treatment

Recent studies indicate that ubrogepant can significantly reduce migraine-related disability if taken at the first sign of an attack.

Ubrogepant is a CGRP inhibitor that targets early migraine symptoms before headache onset.
Clinical trials with 518 participants showed a 73% improvement in normal functioning within two hours of taking the drug.
Participants reported reduced migraine impact, with 65% experiencing minimal to no symptoms after 24 hours.
The drug is effective only for individuals who can detect early warning signs of a migraine.
Research funded by AbbVie suggests potential for improved quality of life for migraine sufferers.